Rachel L. West
Erasmus University Rotterdam
Internal medicineRadiologySurgeryMagnetic resonance imagingRetrospective cohort studyRandomized controlled trialProspective cohort studyAdverse effectCohort studyVedolizumabInfliximabExternal anal sphincterInflammatory bowel diseaseMaintenance therapyUstekinumabDiseaseCrohn's diseaseConcomitantAdalimumabUlcerative colitisSphincterInternal anal sphincterAnal sphincterEndoanal ultrasonographyIn patientMedicineGastroenterology
57Publications
16H-index
1,165Citations
Publications 58
Newest
BACKGROUND Knowledge of the cost of illness of inflammatory bowel disease (IBD) is essential for health policy makers worldwide. AIM To assess the cost of illness of IBD from the societal perspective taking into account time trends and geographical differences. METHODS A systematic review of all population-based studies on cost of illness of IBD published in Embase, Medline, Web of Science and Google Scholar. Methodology of included studies was assessed and costs were adjusted to 2018 US dollars...
Source
Abstract Background & Aims Vitamin D deficiency is common in Crohn’s disease (CD). High-dose vitamin D had anti-inflammatory effects in preclinical studies and trials of patients with CD. We performed a randomized trial to determine whether high-dose vitamin D prevents postoperative recurrence of CD after ileocolonic resection. Methods Patients with CD following ileocolonic resection with ileocolonic anastomosis were randomly assigned to groups given weekly 25,000 IU oral vitamin D (n=72) or pla...
1 CitationsSource
Background and aim null Re-induction with intravenous ustekinumab after secondary loss of response in Crohn's disease is a relatively new strategy to regain efficacy. This real-world cohort study aimed to evaluate its effectiveness and safety. null Methods null Crohn's disease patients with loss of response after initial response to ustekinumab and treated with a second intravenous dose of ustekinumab were included. Clinical, biochemical and endoscopic data were collected. Primary outcome was dr...
Source
#1Pepijn W. A. Thomas (Radboud University Nijmegen)H-Index: 1
#2Tessa E H Römkens (Bosch)H-Index: 13
Last. Frank Hoentjen (Radboud University Nijmegen)H-Index: 16
view all 8 authors...
BACKGROUND Only limited data is available on the extent and burden of adverse drug reactions (ADRs) to biological therapy in inflammatory bowel disease (IBD) patients in daily practice, especially from a patient's perspective. OBJECTIVE The aim of this study was to systematically assess patient-reported ADRs during biological therapy in IBD patients and compare these with healthcare provider (HCP)-reported ADRs. METHODS This multicentre, prospective, event monitoring study enrolled IBD patients ...
Source
#1Eelco C. Brand (UU: Utrecht University)H-Index: 8
#2Marjolein A Y Klaassen (UMCG: University Medical Center Groningen)H-Index: 2
Last. Mariëlle Romberg-CampsH-Index: 22
view all 49 authors...
ABSTRACT Background & aims It is currently unclear whether reported changes in the gut microbiome are cause or consequence of inflammatory bowel disease (IBD). Therefore, we studied the gut microbiome of IBD-discordant and -concordant twin pairs, which offers the unique opportunity to assess individuals at increased risk of developing IBD, namely healthy cotwins from IBD-discordant twin pairs. Methods Fecal samples were obtained from 99 twins (belonging to 51 twin pairs), 495 healthy age-, sex- ...
3 CitationsSource
#1Arno R. Bourgonje (UMCG: University Medical Center Groningen)H-Index: 10
Last. Gerard Dijkstra (UMCG: University Medical Center Groningen)H-Index: 59
view all 10 authors...
In the wake of the coronavirus disease 2019 (COVID-19) pandemic, it is unclear how asymptomatic severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-infected patients who present with acute...
Source
#1Tessa StraatmijerH-Index: 1
Last. Andrea E. van der Meulen-de Jong (LEI: Leiden University)H-Index: 22
view all 20 authors...
Objective Ustekinumab is a monoclonal antibody that selectively targets p40, a shared subunit of the cytokines interleukin (IL)-12 and IL-23. It is registered for the treatment of inflammatory bowel diseases. We assessed the two-year effectiveness and safety of ustekinumab in a real world, prospective cohort of patients with Crohn's disease (CD). Methods Patients who started ustekinumab were prospectively enrolled in the nationwide Initiative on Crohn and Colitis (ICC) Registry. At week 0, 12, 2...
1 CitationsSource
#1Lauranne A A P Derikx (Radboud University Nijmegen)H-Index: 11
#2Marten A. Lantinga (Radboud University Nijmegen)H-Index: 9
Last. Frank Hoentjen (Radboud University Nijmegen)H-Index: 16
view all 25 authors...
BACKGROUND AND AIMS The COVID-19 risk and disease course in inflammatory bowel disease [IBD] patients remains uncertain. Therefore, we aimed to assess the clinical presentation, disease course, and outcomes of COVID-19 in IBD patients. Second, we determined COVID-19 incidences in IBD patients and compared this with the general population. METHODS We conducted a multicentre, nationwide IBD cohort study in The Netherlands and identified patients with COVID-19. First, we assessed the COVID-19 disea...
12 CitationsSource
#1Pepijn W. A. Thomas (Radboud University Nijmegen)H-Index: 1
#2Rachel L. WestH-Index: 16
view all 9 authors...
Purpose To assess the agreement between patient-reported and health care provider-reported medical information in inflammatory bowel disease (IBD). Methods This multicentre, prospective, event monitoring study enrolled adult Crohn's disease (CD) and ulcerative colitis (UC) patients treated with a biological in four medical centres in the Netherlands. At two-monthly intervals, patients completed questionnaires on biological use, combination therapy and indication. The patient-reported information...
1 CitationsSource
#1Eline L. GiraudH-Index: 1
#2Ibdream registry (Radboud University Nijmegen)
Last. Frank Hoentjen (Radboud University Nijmegen)H-Index: 16
view all 11 authors...
INTRODUCTION Inflammatory bowel disease (IBD) frequently requires chronic immunosuppressive treatment and active involvement from patients during treatment decision making. Information about the risk of developing adverse drug reactions (ADRs) to IBD therapies is required in this process. OBJECTIVE The aim of this study was to describe the ADRs reported in IBD patients from real-world data, using the Dutch nationwide IBDREAM registry, and compare the occurrence and cumulative incidences with the...
Source